EU yes for Vertex's Kalydeco in cystic fibrosis
This article was originally published in Scrip
Executive Summary
The European Commission has approved Vertex Pharmaceuticals’ cystic fibrosis drug Kalydeco (ivacaftor), which received CHMP recommendation just two months ago (scripintelligence.com, 25 May 2012).